Evidence map›Paper›PMID 39559359›Full record

ArticleFrontiers in immunology2024

Assessing sepsis-induced immunosuppression to predict positive blood cultures.

Enrique Hernández-Jiménez, Erika P Plata-Menchaca, Damaris Berbel, Guillem López de Egea, Macarena Dastis-Arias, Laura García-Tejada, Fabrizio Sbraga, Pierre Malchair, Nadia García Muñoz, Alejandra Larrad Blasco and 4 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Review
  6. Article
  7. Review
  8. From sepsis biomarker discovery to regulatedFrontiers in medical technology · 2026
    Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Enrique Hernández-JiménezR&D Department, Loop Diagnostics, Barcelona, Spain.
Erika P Plata-MenchacaServei de Medicina Intensiva, Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Damaris BerbelDepartament de Microbiologia, Hospital Universitari de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Guillem López de EgeaDepartament de Microbiologia, Hospital Universitari de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Macarena Dastis-AriasDivision of Emergency Laboratory, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain.
Laura García-TejadaBiochemistry Core of the Clinical Laboratory, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain.
Fabrizio SbragaServei de Cirurgia Cardíaca, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain.
Pierre MalchairDepartament d'urgències, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain.
Nadia García MuñozBanc de sang i teixits, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain.
Alejandra Larrad BlascoServei de Medicina Intensiva, Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Eva Molina RamírezServei de Medicina Intensiva, Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Xose Pérez FernándezServei de Medicina Intensiva, Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Joan Sabater Riera *Servei de Medicina Intensiva, Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Arnau Ulsamer *Servei de Medicina Intensiva, Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Bacteremia is a life-threatening condition that can progress to sepsis and septic shock, leading to significant mortality in the emergency department (ED). The standard diagnostic method, blood culture, is time-consuming and prone to false positives and false negatives. Although not widely accepted, several clinical and artificial intelligence-based algorithms have been recently developed to predict bacteremia. However, these strategies require further identification of new variables to improve their diagnostic accuracy. This study proposes a novel strategy to predict positive blood cultures by assessing sepsis-induced immunosuppression status through endotoxin tolerance assessment. Methods: Optimal assay conditions have been explored and tested in sepsis-suspected patients meeting the Sepsis-3 criteria. Blood samples were collected at ED admission, and endotoxin (lipopolysaccharide, LPS) challenge was performed to evaluate the innate immune response through cytokine profiling. Results: Clinical variables, immune cell population biomarkers, and cytokine levels (tumor necrosis factor [TNFα], IL-1β, IL-6, IL-8, and IL-10) were measured. Patients with positive blood cultures exhibited significantly lower TNFα production after LPS challenge than did those with negative blood cultures. The study also included a validation cohort to confirm that the response was consistent. Discussion: The results of this study highlight the innate immune system immunosuppression state as a critical parameter for sepsis diagnosis. Notably, the present study identified a reduction in monocyte populations and specific cytokine profiles as potential predictive markers. This study showed that the LPS challenge can be used to effectively distinguish between patients with bloodstream infection leading to sepsis and those whose blood cultures are negative, providinga rapid and reliable diagnostic tool to predict positive blood cultures. The potential applicability of these findings could enhance clinical practice in terms of the accuracy and promptness of sepsis diagnosis in the ED, improving patient outcomes through timely and appropriate treatment.

Indexed as

BiomarkersBlood CultureSepsisAdultAgedBacteremiaCytokinesFemaleHumansImmune ToleranceImmunity, InnateLipopolysaccharidesMaleMiddle AgedMonocytesBiomarkersCytokinesLipopolysaccharidesbacteremiabiomarkersblood cultureendotoxin toleranceimmunosuppressionLPSsepsisTNFα

Identifiers

PMID39559359
PMCPMC11570276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.